Invanz
153773-82-1
497.5
C22H24N3NaO7S
Water
2-8°C
Ertapenem is a new carbapenem which has β-Lactam features and is regarded as having the most potent and the widest spectrum of antimicrobial activity, like imipenem and meropenem. It is effective against both Gram-negative and Gram-positive aerobes and anaerobes and is resistant to nearly all beta-lactamases, including extended-spectrum Beta-lactamases and AmpCs.
Ertapenem has a mechanism that suppresses synthesis of bacterial cell walls. The drug binds to penicillin binding proteins (PBPs), especially PBPs 2 and 3, on bacterial cell walls and inhibits the synthesis of peptidoglycan by interfering the final transpeptidation step.
Ertapenem is approved in the US and the EU as a parenteral infection treatment. It is used for intra-abdominal infection, complicated skin and soft-tissue infections, community-acquired pneumonia and acute pelvic infection.
0.1 lbs
Research or further manufacturing use only, not for food or drug use.
